哮喘中的生物标志物：最新进展
Biomarkers in asthma: state of the art.
作者信息
Tiotiu Angelica
机构信息
1Pulmonology Department, University Hospital, 9, Rue du Morvan, 54511 Nancy, Vandœuvre-lès-Nancy France.
2EA 3450 DevAH, Development, Adaptation, Cardio-Respiratory Regulations and Motor Control, University of Lorraine, Nancy, France.
出版信息
Asthma Res Pract. 2018 Dec 21;4:10. doi: 10.1186/s40733-018-0047-4. eCollection 2018.
Asthma is a heterogenous disease characterized by multiple phenotypes driven by different mechanisms. The implementation of precision medicine in the management of asthma requires the identification of phenotype-specific markers measurable in biological fluids. To become useful, these biomarkers need to be quantifiable by reliable systems, reproducible in the clinical setting, easy to obtain and cost-effective. Using biomarkers to predict asthma outcomes and therapeutic response to targeted therapies has a great clinical significance, particularly in severe asthma. In the last years, significant research has been realized in the identification of valid biomarkers for asthma. This review focuses on the existent and emerging biomarkers with clinical higher applicability in the management of asthma.
哮喘是一种异质性疾病，具有由不同机制驱动的多种表型。在哮喘管理中实施精准医学需要识别可在生物体液中测量的表型特异性标志物。为了发挥作用，这些生物标志物需要通过可靠的系统进行量化，在临床环境中可重复，易于获取且具有成本效益。使用生物标志物预测哮喘结局和对靶向治疗的治疗反应具有重要的临床意义，尤其是在重度哮喘中。近年来，在识别有效的哮喘生物标志物方面已经取得了重大研究进展。本综述重点关注在哮喘管理中具有更高临床适用性的现有和新兴生物标志物。
Zotero 插件